drugset / Trial / NCT05227651
AK104 in Neoadjuvant Treatment of Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
Timeline
- Start
- 2023-02-10
- Primary completion
- 2024-09-27
- Completion
- 2024-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |